179 related articles for article (PubMed ID: 37711809)
1. Development of a novel tumor microenvironment-related radiogenomics model for prognosis prediction in hepatocellular carcinoma.
Wang Y; Gao B; Xia C; Peng X; Liu H; Wu S
Quant Imaging Med Surg; 2023 Sep; 13(9):5803-5814. PubMed ID: 37711809
[TBL] [Abstract][Full Text] [Related]
2. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
Gao J; Ye F; Han F; Jiang H; Zhang J
Front Immunol; 2022; 13():956679. PubMed ID: 36177018
[TBL] [Abstract][Full Text] [Related]
3. From imaging to clinical outcome: dual-region CT radiomics predicting FOXM1 expression and prognosis in hepatocellular carcinoma.
Chen X; Tang Y; Wu D; Li R; Lin Z; Zhou X; Wang H; Zhai H; Xu J; Shi X; Zhang G
Front Oncol; 2023; 13():1278467. PubMed ID: 37817774
[TBL] [Abstract][Full Text] [Related]
4. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
5. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
7. A Novel Radiogenomics Biomarker Based on Hypoxic-Gene Subset: Accurate Survival and Prognostic Prediction of Renal Clear Cell Carcinoma.
Gao J; Ye F; Han F; Wang X; Jiang H; Zhang J
Front Oncol; 2021; 11():739815. PubMed ID: 34692518
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
9. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.
Wang D; Zhang L; Sun Z; Jiang H; Zhang J
Eur J Radiol; 2023 Oct; 167():111086. PubMed ID: 37708675
[TBL] [Abstract][Full Text] [Related]
10. Immune landscape of hepatocellular carcinoma tumor microenvironment identifies a prognostic relevant model.
Cao H; Huang P; Qiu J; Gong X; Cao H
Heliyon; 2024 Feb; 10(3):e24861. PubMed ID: 38317886
[TBL] [Abstract][Full Text] [Related]
11. Contrast-Enhanced Computed Tomography-Based Radiogenomics Analysis for Predicting Prognosis in Gastric Cancer.
Liu H; Wang Y; Liu Y; Lin D; Zhang C; Zhao Y; Chen L; Li Y; Yuan J; Chen Z; Yu J; Kong W; Chen T
Front Oncol; 2022; 12():882786. PubMed ID: 35814414
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis.
Qu C; Wu Q; Lu J; Li F
Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188
[TBL] [Abstract][Full Text] [Related]
13. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
14. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an eight-gene signature based predictive model to evaluate the prognosis of hepatocellular carcinoma patients: a bioinformatic study.
Zhang J; Fu X; Zhang N; Wang W; Liu H; Jia Y; Nie Y
Ann Transl Med; 2022 May; 10(9):524. PubMed ID: 35928748
[TBL] [Abstract][Full Text] [Related]
16. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
17. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
18. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.
Lin P; Wen DY; Chen L; Li X; Li SH; Yan HB; He RQ; Chen G; He Y; Yang H
Eur Radiol; 2020 Jan; 30(1):547-557. PubMed ID: 31396730
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
20. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
